A citation-based method for searching scientific literature

Anees Bahji, Gustavo H Vazquez, Carlos A Zarate. J Affect Disord 2021
Times Cited: 55







List of co-cited articles
524 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
38

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
30

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
818
25

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
278
23

Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Gustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, Manuela Telles, Rodrigo P Mello, Flavia Vieira, Cassio S Lima, Ana Paula Jesus-Nunes, Lívia N F Guerreiro-Costa, Roberta F Marback,[...]. Eur Arch Psychiatry Clin Neurosci 2021
85
21

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
Fernanda S Correia-Melo, Gustavo C Leal, Flávia Vieira, Ana Paula Jesus-Nunes, Rodrigo P Mello, Guilherme Magnavita, Ana Teresa Caliman-Fontes, Mariana V F Echegaray, Igor D Bandeira, Samantha S Silva,[...]. J Affect Disord 2020
59
20

Mechanisms of ketamine action as an antidepressant.
P Zanos, T D Gould. Mol Psychiatry 2018
327
20

Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials.
Katrina Witt, Jennifer Potts, Anna Hubers, Michael F Grunebaum, James W Murrough, Colleen Loo, Andrea Cipriani, Keith Hawton. Aust N Z J Psychiatry 2020
58
18

Ketamine: A tale of two enantiomers.
Luke A Jelen, Allan H Young, James M Stone. J Psychopharmacol 2021
36
27

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Ella J Daly, Jaskaran B Singh, Maggie Fedgchin, Kimberly Cooper, Pilar Lim, Richard C Shelton, Michael E Thase, Andrew Winokur, Luc Van Nueten, Husseini Manji,[...]. JAMA Psychiatry 2018
265
18

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Vanina Popova, Ella J Daly, Madhukar Trivedi, Kimberly Cooper, Rosanne Lane, Pilar Lim, Christine Mazzucco, David Hough, Michael E Thase, Richard C Shelton,[...]. Am J Psychiatry 2019
205
18

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Maurizio Fava, Marlene P Freeman, Martina Flynn, Heidi Judge, Bettina B Hoeppner, Cristina Cusin, Dawn F Ionescu, Sanjay J Mathew, Lee C Chang, Dan V Iosifescu,[...]. Mol Psychiatry 2020
124
18

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Carla M Canuso, Jaskaran B Singh, Maggie Fedgchin, Larry Alphs, Rosanne Lane, Pilar Lim, Christine Pinter, David Hough, Gerard Sanacora, Husseini Manji,[...]. Am J Psychiatry 2018
202
18

Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Jennifer L Phillips, Sandhaya Norris, Jeanne Talbot, Meagan Birmingham, Taylor Hatchard, Abigail Ortiz, Olabisi Owoeye, Lisa A Batten, Pierre Blier. Am J Psychiatry 2019
133
18

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
18

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Carlos A Zarate, Nancy E Brutsche, Lobna Ibrahim, Jose Franco-Chaves, Nancy Diazgranados, Anibal Cravchik, Jessica Selter, Craig A Marquardt, Victoria Liberty, David A Luckenbaugh. Biol Psychiatry 2012
500
18

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
James W Murrough, Dan V Iosifescu, Lee C Chang, Rayan K Al Jurdi, Charles E Green, Andrew M Perez, Syed Iqbal, Sarah Pillemer, Alexandra Foulkes, Asim Shah,[...]. Am J Psychiatry 2013
673
18

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
18


Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Lace M Riggs, Jaclyn N Highland, Polymnia Georgiou, Edna F R Pereira, Edson X Albuquerque, Craig J Thomas, Carlos A Zarate,[...]. Pharmacol Rev 2018
372
16

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Ewa Wajs, Leah Aluisio, Richard Holder, Ella J Daly, Rosanne Lane, Pilar Lim, Joyce E George, Randall L Morrison, Gerard Sanacora, Allan H Young,[...]. J Clin Psychiatry 2020
84
16

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados, Lobna Ibrahim, Nancy E Brutsche, Andrew Newberg, Phillip Kronstein, Sami Khalife, William A Kammerer, Zenaide Quezado, David A Luckenbaugh, Giacomo Salvadore,[...]. Arch Gen Psychiatry 2010
650
16

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Gerard Sanacora, Mark A Frye, William McDonald, Sanjay J Mathew, Mason S Turner, Alan F Schatzberg, Paul Summergrad, Charles B Nemeroff. JAMA Psychiatry 2017
251
16

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Ella J Daly, Madhukar H Trivedi, Adam Janik, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna R Duca, David Hough,[...]. JAMA Psychiatry 2019
166
16

The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Jiaqi Xiong, Orly Lipsitz, David Chen-Li, Joshua D Rosenblat, Nelson B Rodrigues, Isabelle Carvalho, Leanna M W Lui, Hartej Gill, Flora Narsi, Rodrigo B Mansur,[...]. J Psychiatr Res 2021
25
36

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
314
16

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
Michael F Grunebaum, Hanga C Galfalvy, Tse-Hwei Choo, John G Keilp, Vivek K Moitra, Michelle S Parris, Julia E Marver, Ainsley K Burke, Matthew S Milak, M Elizabeth Sublette,[...]. Am J Psychiatry 2018
171
16


A randomized controlled trial of intranasal ketamine in major depressive disorder.
Kyle A B Lapidus, Cara F Levitch, Andrew M Perez, Jess W Brallier, Michael K Parides, Laili Soleimani, Adriana Feder, Dan V Iosifescu, Dennis S Charney, James W Murrough. Biol Psychiatry 2014
252
14

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji,[...]. Biol Psychiatry 2016
211
14

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, Peter De Boer, Kimberly Cooper, Pilar Lim, Christine Pinter, James W Murrough, Gerard Sanacora, Richard C Shelton,[...]. Am J Psychiatry 2016
260
14

Side-effects associated with ketamine use in depression: a systematic review.
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker, Colleen K Loo. Lancet Psychiatry 2018
193
14

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Nolan R Williams, Boris D Heifets, Christine Blasey, Keith Sudheimer, Jaspreet Pannu, Heather Pankow, Jessica Hawkins, Justin Birnbaum, David M Lyons, Carolyn I Rodriguez,[...]. Am J Psychiatry 2018
210
14

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
James W Murrough, Andrew M Perez, Sarah Pillemer, Jessica Stern, Michael K Parides, Marije aan het Rot, Katherine A Collins, Sanjay J Mathew, Dennis S Charney, Dan V Iosifescu. Biol Psychiatry 2013
462
14

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Maggie Fedgchin, Madhukar Trivedi, Ella J Daly, Rama Melkote, Rosanne Lane, Pilar Lim, Dawn Vitagliano, Pierre Blier, Maurizio Fava, Michael Liebowitz,[...]. Int J Neuropsychopharmacol 2019
143
14

Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
C K Loo, V Gálvez, E O'Keefe, P B Mitchell, D Hadzi-Pavlovic, J Leyden, S Harper, A A Somogyi, R Lai, C S Weickert,[...]. Acta Psychiatr Scand 2016
108
14

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. PLoS Med 2009
14

Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis.
Anees Bahji, Dylan Ermacora, Callum Stephenson, Emily R Hawken, Gustavo Vazquez. Can J Psychiatry 2021
9
77

The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
Roger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, Amna Majeed, Prakash S Masand, Hartej Gill, Nelson B Rodrigues, Orly Lipsitz, Alexandria C Coles, Yena Lee,[...]. J Affect Disord 2020
49
14


Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Rachel Ochs-Ross, Ella J Daly, Yun Zhang, Rosanne Lane, Pilar Lim, Randall L Morrison, David Hough, Husseini Manji, Wayne C Drevets, Gerard Sanacora,[...]. Am J Geriatr Psychiatry 2020
95
12

Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Dawn F Ionescu, Kate H Bentley, Matthias Eikermann, Norman Taylor, Oluwaseun Akeju, Michaela B Swee, Kara J Pavone, Samuel R Petrie, Christina Dording, David Mischoulon,[...]. J Affect Disord 2019
70
12

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
825
12

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial.
J W Murrough, L Soleimani, K E DeWilde, K A Collins, K A Lapidus, B M Iacoviello, M Lener, M Kautz, J Kim, J B Stern,[...]. Psychol Med 2015
164
12

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
12

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Roger S McIntyre, Joshua D Rosenblat, Charles B Nemeroff, Gerard Sanacora, James W Murrough, Michael Berk, Elisa Brietzke, Seetal Dodd, Philip Gorwood, Roger Ho,[...]. Am J Psychiatry 2021
70
12

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.
Kenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, Takashi Hashihayata, Jun-Ichi Yamaguchi, Kenji Hashimoto, Shigeyuki Chaki. J Pharmacol Exp Ther 2017
129
12

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
188
12

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
D Jeffrey Newport, Linda L Carpenter, William M McDonald, James B Potash, Mauricio Tohen, Charles B Nemeroff. Am J Psychiatry 2015
343
12

An update on ketamine and its two enantiomers as rapid-acting antidepressants.
Kai Zhang, Kenji Hashimoto. Expert Rev Neurother 2019
58
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.